Naru Sato

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance.

Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance.

Journal: Molecular cancer therapeutics

Published: August 18, 2025

ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights.

ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights.

Journal: International journal of hematology

Published: April 24, 2025

Clonal hematopoiesis-related mutant ASXL1 promotes atherosclerosis in mice via dysregulated innate immunity.

Clonal hematopoiesis-related mutant ASXL1 promotes atherosclerosis in mice via dysregulated innate immunity.

Journal: Nature cardiovascular research

Published: May 03, 2024

Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.

Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.

Journal: Cell reports

Published: December 20, 2022

IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia.

IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia.

Journal: EMBO molecular medicine

Published: December 22, 2021

CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression.

CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression.

Journal: Cancer science

Published: December 07, 2021

A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells.

A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells.

Journal: Cell reports

Published: September 08, 2020

Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.

Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.

Journal: Nature communications

Published: December 05, 2019

ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation.

ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation.

Journal: Scientific reports

Published: January 19, 2018

Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.

Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.

Journal: International journal of hematology

Published: April 13, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026